📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO - LT phase 3, open-label study (2025)

First Author: Tziotzios C

Attributed to: Shared and distinct genetic architecture of autoimmune and hormonal alopecias funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/jdv.20526

PubMed Identifier: 39846397

Publication URI: http://europepmc.org/abstract/MED/39846397

Type: Journal Article/Review

Parent Publication: Journal of the European Academy of Dermatology and Venereology